Why Moderna Shares Are Falling After Child Vaccine Study

The video discusses Moderna's recent vaccine trial data for young children, which showed 40% efficacy. This has led to investor concerns as the typical acceptable lower limit is 50%. The discussion includes insights from Sam Fazeli of Bloomberg Intelligence and compares the current data with previous high efficacy rates during earlier variants. The video questions the fairness of such comparisons due to Omicron's immune evasive nature.

What was the efficacy rate of Moderna's vaccine trial for young children?

• 50%

• 40%

• 60%

• 30%

What is the generally accepted lower limit for vaccine efficacy?

• 60%

• 50%

• 40%

• 30%

Who provided insights on the potential approval of Moderna's vaccine?

• Bloomberg News

• Ritika Gupta

• Caroline

• Sam Fazeli

Why might comparisons to previous vaccine efficacy rates be considered unfair?

• The vaccine was not widely distributed

• The data was not peer-reviewed

• The Omicron variant is immune-evasive

• The trial size was smaller

What was the efficacy rate of vaccines during earlier variants like prio macrum?

• 85%

• 90%

• 95%

• 100%